公开(公告)号：WO2014018274A8

公开(公告)日：2015-03-12

申请号：PCT/US2013050058

申请日：2013-07-11

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： BARRETT NOEL P ,  AICHINGER GERALD ,  CROWE BRIAN A ,  LIVEY IAN ,  WRESSNIGG NINA

IPC: A61K39/02 ,  A61P31/04 ,  C07K16/12

CPC classification number: A61K38/164 ,  A61K39/0225 ,  A61K2039/55505 ,  A61K2039/58 ,  A61K2039/70 ,  C07K16/1207 ,  C07K2317/33

Abstract: The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

Abstract translation: 本发明涉及用于新的莱姆疫苗的嵌合OspA分子的开发。 更具体地，嵌合OspA分子包含来自一个OspA血清型的近端部分以及来自另一种OspA血清型的远端部分，同时保留两种亲本多肽的抗原性质。 嵌合的OspA分子单独或组合递送以提供针对各种疏螺旋体种属的保护。 本发明还提供了在预防和治疗莱姆病或硼状血症中向受试者施用嵌合OspA分子的方法。

公开(公告)号：WO2011041478A8

公开(公告)日：2014-10-09

申请号：PCT/US2010050812

申请日：2010-09-30

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  AMRANI DAVID L ,  MOTLAGH DELARA ,  HOFF CATHERINE M ,  COHEN AMY ,  DUFFIELD JEREMY

Inventor： AMRANI DAVID L ,  MOTLAGH DELARA ,  HOFF CATHERINE M ,  COHEN AMY ,  DUFFIELD JEREMY

IPC: A61K35/14 ,  A61K35/28 ,  A61P13/12

CPC classification number: A61K35/28 ,  A61K31/185 ,  A61K31/495 ,  A61K38/1709 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided herein are methods of treating a kidney injury in a patient, comprising administering to the patient hematopoietic stem cells (HSCs) in an amount effective to treat the kidney injury. In some embodiments, administration of the HSCs is delayed, such that the HSCs are not administered immediately after the kidney injury. In certain aspects, the HSCs are administered to the patient during the beginning of the repair phase of the kidney. Further embodiments and aspects of the invention, including related methods and compositions for use therein, are described herein.

Abstract translation: 本文提供了治疗患者的肾损伤的方法，包括以有效治疗肾损伤的量向患者施用造血干细胞（HSC）。 在一些实施方案中，HSC的施用被延迟，使得HSC在肾损伤后不立即施用。 在某些方面，在肾脏的修复阶段开始期间将HSC施用于患者。 本文描述了本发明的其它实施方案和方面，包括用于其中的相关方法和组合物。

公开(公告)号：WO2013106772A3

公开(公告)日：2014-01-09

申请号：PCT/US2013021313

申请日：2013-01-11

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  MALISAUSKAS MANTAS ,  LUBICH CHRISTIAN ,  PRENNINGER THOMAS ,  REIPERT BIRGIT

Inventor： MALISAUSKAS MANTAS ,  LUBICH CHRISTIAN ,  PRENNINGER THOMAS ,  REIPERT BIRGIT

IPC: G01N33/483 ,  G01N15/10 ,  G01N33/68

CPC classification number: G01N33/6839 ,  C12Q1/56 ,  G01N15/1012 ,  G01N15/1429 ,  G01N33/48735 ,  G01N33/6803 ,  G01N33/86 ,  G01N2015/1493

Abstract: The present specification discloses methods of characterizing a population of particles using a particle analyzer. Particles may be characterized by size, absolute number, whether the particle is non-proteinaceous or proteinaceous, whether a proteinaceous particle has or lacks a certain physical property, or any combination thereof.

Abstract translation: 本说明书公开了使用粒子分析仪表征粒子群体的方法。 粒子的特征可以是大小，绝对数，颗粒是非蛋白质还是蛋白质，蛋白质颗粒是否具有或缺乏一定的物理性质，或其任何组合。

公开(公告)号：WO2013053749A3

公开(公告)日：2013-11-14

申请号：PCT/EP2012070050

申请日：2012-10-10

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： HARKAMP KATHARINA ,  GORNA KATARZYNA ,  TSCHETSCHKOWITSCH KLAUS

IPC: A61L24/04 ,  A61L24/08 ,  A61L26/00

CPC classification number: A61K31/722 ,  A61L24/043 ,  A61L24/08 ,  A61L26/0023 ,  A61L26/0052 ,  A61L2400/04 ,  A61M5/19 ,  C08L5/08

Abstract: The invention discloses a hemostatic composition comprising chitin or a water insoluble chitin derivative, especially water insoluble chitosan, in particulate form, wherein the composition is present in paste form.

Abstract translation: 本发明公开了一种止血组合物，其包含颗粒形式的几丁质或水不溶性几丁质衍生物，特别是水不溶性壳聚糖，其中所述组合物以糊状形式存在。

公开(公告)号：WO2013126590A3

公开(公告)日：2013-10-31

申请号：PCT/US2013027163

申请日：2013-02-21

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA

Inventor： PALMER LORA ,  MOTLAGH DELARA ,  COHEN AMY ,  AMRANI DAVID L

IPC: A61K35/14 ,  A61K35/12 ,  A61K47/00 ,  A61P9/10 ,  C12N5/071

CPC classification number: A61K35/14 ,  A61K9/0019 ,  A61K35/12 ,  A61K35/15 ,  A61K47/12 ,  A61K47/42 ,  A61K2035/124

Abstract: The invention relates to the field of treatment of ischemic conditions and diseases using a cell population comprising CD34+ cells isolated from peripheral blood of a subject. The invention provides a pharmaceutical composition comprising (i) a cell population comprising CD34+ cells, (ii) a plasma protein, and (iii) an isotonic solution comprising at least one salt, said isotonic solution comprising acetate, gluconate, or both acetate and gluconate. Methods of treating tissue damaged by ischemia in a subject and methods of treating a medical condition, wherein the pharmaceutical composition of the invention is administered, are further provided herein. Also, methods of promoting mobilization of CD34+ cells from bone marrow into peripheral blood are provided herein.

Abstract translation: 本发明涉及使用包含从受试者的外周血分离的CD34 +细胞的细胞群治疗缺血性病症和疾病的领域。 本发明提供了药物组合物，其包含（i）包含CD34 +细胞的细胞群，（ii）血浆蛋白，和（iii）包含至少一种盐的等渗溶液，所述等渗溶液包含乙酸盐，葡萄糖酸盐或乙酸盐和葡萄糖酸盐二者 。 本文进一步提供了治疗受试者缺血损伤组织的方法和治疗医学病症的方法，其中施用本发明的药物组合物。 此外，本文提供促进CD34 +细胞从骨髓迁移至外周血的方法。

公开(公告)号：WO2009105413A3

公开(公告)日：2013-08-08

申请号：PCT/US2009034249

申请日：2009-02-17

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  BEDINGFIELD JOHN ,  LAUMAN BRIAN

Inventor： BEDINGFIELD JOHN

IPC: A61M5/44 ,  A61M1/16 ,  A61M1/28 ,  F24H1/10 ,  F24H9/20

CPC classification number: F24H9/2028 ,  A61M1/166 ,  A61M1/28 ,  A61M1/282 ,  A61M5/445 ,  A61M2205/3653 ,  F24H1/101

Abstract: A dialysis machine having a multiple line voltage heater includes first and second heater elements, first and second switching devices connected electrically to the first and second heating elements, first and second power lines, and a control element configured to provide a first switching device state in which power at a first voltage is supplied via the first and second power lines to both first and second heater elements via both first and second switching devices and a second switching device state in which power at a second voltage is supplied via the first and second power lines to the first heater element only via the first switching device.

Abstract translation: 具有多线电压加热器的透析机包括第一和第二加热器元件，电连接到第一和第二加热元件的第一和第二开关器件，第一和第二电力线以及控制元件，其被配置为提供第一开关器件状态 经由第一和第二电源线经由第一和第二开关装置经由第一和第二电力线向第一和第二加热器元件提供第一电压的第二开关装置状态和经由第一和第二电力供应第二电压的电力的第二开关装置状态 仅通过第一开关装置将线路连接到第一加热器元件。

公开(公告)号：WO2012159700A8

公开(公告)日：2013-06-06

申请号：PCT/EP2012001768

申请日：2012-04-25

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  WEBER ALFRED ,  ENGELMAIER ANDREA ,  SCHWARZ HANS-PETER

Inventor： WEBER ALFRED ,  ENGELMAIER ANDREA ,  SCHWARZ HANS-PETER

IPC: G01N33/53 ,  G01N33/68

CPC classification number: G01N33/68 ,  G01N33/53 ,  G01N2333/8125 ,  G01N2333/966

Abstract: The present invention relates to a method for the measurement of active alpha1-proteinase inhibitor (A1PI) in a sample, comprising the steps of binding elastase to a solid support, letting the A1PI contained in the sample bind to the solid phase-bound elastase, and detecting solid phase-bound A1PI with a detection reagent.

Abstract translation: 本发明涉及一种用于测量样品中活性α1-蛋白酶抑制剂（A1PI）的方法，包括以下步骤：将弹性蛋白酶与固体支持物结合，使样品中包含的A1PI与固相结合的弹性蛋白酶结合， 并用检测试剂检测固相键A1PI。

公开(公告)号：WO2012171983A3

公开(公告)日：2013-05-10

申请号：PCT/EP2012061253

申请日：2012-06-14

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  DELMOTTE YVES

Inventor： DELMOTTE YVES

IPC: C08L5/04 ,  A61K38/36 ,  B01F13/00 ,  C07K14/75 ,  C07K14/78 ,  C08L5/08 ,  C08L89/00 ,  C08L89/06

CPC classification number: C12P21/00 ,  B01F13/0071 ,  C07K1/02 ,  C07K14/75 ,  C07K14/765 ,  C07K14/78 ,  C08L5/04 ,  C08L5/08 ,  C08L89/00 ,  C08L89/06 ,  C12N9/54

Abstract: The invention discloses a method for the production of a polymerized product comprising the following steps: - providing a polymerization device to which a polymerization mixture and a separation medium can be applied and wherein flow of said mixture and medium can be conducted in appropriate ducts for said mixture and medium, - transporting said polymerization mixture in a duct of said polymerization device thereby allowing the polymerization reaction, - transporting said mixture in a duct of said polymerization device in a continuous flow, - interrupting said continuous flow of said mixture with said separation medium so as to obtain consecutive volumes of said mixture and volumes of said separation medium, - further transporting said consecutive volumes of said mixture and volumes of said separation medium in a duct of said polymerization device wherein said mixture further polymerizes to obtain a discontinuous polymerized product, and removing said discontinuous polymerized product from said polymerization device.

Abstract translation: 本发明公开了一种生产聚合产物的方法，包括以下步骤： - 提供聚合装置，聚合混合物和分离介质可以被施加到聚合装置上，并且所述混合物和介质的流动可以在适当的管道中进行，用于所述 混合物和介质， - 将所述聚合混合物输送在所述聚合装置的管道中，从而允许聚合反应，以连续流动方式在所述聚合装置的管道中输送所述混合物， - 用所述分离介质中断所述混合物的所述连续流动 以便获得所述分离介质的所述混合物和体积的连续体积， - 在所述聚合装置的管道中进一步输送所述连续体积的所述分离介质的所述混合物和体积，其中所述混合物进一步聚合以获得不连续的聚合产物， 并除去所述不连续聚合产物 从所述聚合装置。

公开(公告)号：WO2013012954A3

公开(公告)日：2013-03-21

申请号：PCT/US2012047248

申请日：2012-07-18

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  TURECEK PETER ,  VEJDA SUSANNE

Inventor： TURECEK PETER ,  VEJDA SUSANNE

IPC: A61K31/737 ,  A61K9/08 ,  A61K9/10 ,  A61K31/715 ,  A61K31/726 ,  A61K38/17 ,  A61P1/00

CPC classification number: A61K38/4846 ,  A61K38/4853 ,  A61K45/06 ,  A61K47/12 ,  A61K47/28 ,  A61K47/36 ,  A61K47/42 ,  A61K2300/00

Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.

Abstract translation: 本发明的各方面包括用于增强受试者的凝血的方法。 在根据某些实施方案的实践方法中，一定量的非抗凝血硫酸化多糖（NASP）与胃肠上皮屏障渗透促进剂的组合以足以增强受试者中凝血的方式口服给予受试者。 还描述了用于实施本发明方法的组合物和试剂盒。

公开(公告)号：WO2012122018A2

公开(公告)日：2012-09-13

申请号：PCT/US2012027478

申请日：2012-03-02

Applicant: BAXTER INT ,  BAXTER HEALTHCARE SA ,  CHEN YE ,  DING YUANPANG SAMUEL ,  MULLER MATTHEW ,  NAJDENI GERT ,  TITUS JOEL

Inventor： CHEN YE ,  DING YUANPANG SAMUEL ,  MULLER MATTHEW ,  NAJDENI GERT ,  TITUS JOEL

IPC: G01F23/284 ,  A61M1/16

CPC classification number: G01F23/263 ,  A61M1/14 ,  A61M1/16 ,  A61M1/1605 ,  A61M1/1607 ,  A61M1/1668 ,  A61M1/28 ,  A61M1/287 ,  A61M5/14 ,  A61M5/1407 ,  A61M5/1409 ,  A61M5/142 ,  A61M5/1684 ,  A61M2205/3317 ,  A61M2205/3379 ,  A61M2205/3389 ,  A61M2205/52 ,  G01F22/00 ,  G01F23/26 ,  G01F23/284

Abstract: A medical fluid system includes a medical fluid pump; a container holding a fluid to be pumped by the medical fluid pump, the fluid at a first time having a first conductivity, the fluid at a second time having a second conductivity; and a radio frequency level sensor positioned in operable relation with the container, the radio frequency operation of the level sensor configured so as to be (i) indicative of a level of the fluid in the container and (ii) at least substantially independent of whether the fluid has the first conductivity or the second conductivity. The medical fluid system can determine the level of medical fluid by measuring the resistance, impedance or phase shift seen by the sensor.

Abstract translation: 医疗流体系统包括医用流体泵; 容纳由所述医用流体泵泵送的流体的容器，所述流体在第一时间具有第一导电性，所述流体在第二时间具有第二导电性; 和与所述容器可操作关系的射频水平传感器，所述液位传感器的射频操作被配置为（i）指示所述容器中的液体的水平，以及（ii）至少基本上不依赖于是否 流体具有第一导电性或第二导电性。 医疗流体系统可以通过测量传感器所看到的电阻，阻抗或相位差来确定医疗流体的水平。